Home Microbiology HIV inhibitor ABX464

research use only

ABX464 HIV inhibitor

Cat.No.S0076

ABX464 (SPL-464) is a novel anti-HIV molecule that inhibits HIV-1 replication in stimulated peripheral blood mononuclear cells (PBMCs) from 5 different donors with IC50 ranging between 0.1 μM and 0.5 μM.
ABX464 HIV inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 338.71

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability

Quality Control

Batch: S007601 DMSO]68 mg/mL]false]Ethanol]68 mg/mL]false]Water]Insoluble]false Purity: 99.98%
99.98

Chemical Information, Storage & Stability

Molecular Weight 338.71 Formula

C16H10ClF3N2O

 Storage (From the date of receipt) 3 years -20°C powder
CAS No. 1258453-75-6 -- Storage of Stock Solutions

Synonyms SPL-464 Smiles C1=CC2=C(C(=C1)Cl)N=C(C=C2)NC3=CC=C(C=C3)OC(F)(F)F

Solubility

In vitro
Batch:

DMSO : 68 mg/mL (200.76 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 68 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
HIV-1 [1]
(Cell-free assay)
0.1 μM
HIV-1 [1]
(Cell-free assay)
0.5 μM
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05177835 Active not recruiting
Ulcerative Colitis
Abivax S.A.
 December 3 2021 Phase 2
NCT05121714 Completed
Healthy
Abivax S.A.
 December 17 2020 Phase 1
NCT03905109 Unknown status
Crohn Disease
Abivax S.A.
 April 15 2020 Phase 2
NCT04023396 Unknown status
Ulcerative Colitis
Abivax S.A.
 January 13 2020 Phase 2
NCT04049448 Completed
Rheumatoid Arthritis
Abivax S.A.
 October 24 2019 Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.